((6S,8S)-6-[({(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-8-methyl-4-oxo-3-{[3-(trifluoromethyl)benzyl]amino}-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidin-8-yl)acetic acid | 437761-37-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: ((6S,8S)-6-[({(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-8-methyl-4-oxo-3-{[3-(trifluoromethyl)benzyl]amino}-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidin-8-yl)acetic acid
• 英文别名: 2-[(6S,8S)-8-methyl-4-oxo-3-[[3-(trifluoromethyl)phenyl]methylamino]-6-[[(1R)-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]propyl]carbamoyl]-6,7-dihydropyrrolo[1,2-a]pyrimidin-8-yl]acetic acid
• CAS: 437761-37-0
• 化学式: C₃₂H₄₀BF₃N₄O₆
• 分子量: 644.499
• InChiKey: LWVBEVXRCJWEOW-GSMUGVNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  46
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  3-氨基茴香硫醚 、 ((6S,8S)-6-[({(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-8-methyl-4-oxo-3-{[3-(trifluoromethyl)benzyl]amino}-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidin-8-yl)acetic acid 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 生成 (6S,8S)-8-methyl-8-[2-(3-methylsulfanylanilino)-2-oxoethyl]-4-oxo-3-[[3-(trifluoromethyl)phenyl]methylamino]-N-[(1R)-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]propyl]-6,7-dihydropyrrolo[1,2-a]pyrimidine-6-carboxamide
  参考文献：
  名称：

  Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors

  摘要：

  A series of bicyclic pyrimidinone-based HCV NS3 protease inhibitors was synthesized via selective C8 position functionalization. Substituted phenylamides and phenylureas were preferred in the S2 binding pocket. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00022-2
• 作为产物：
  描述：

  (6S,8S)-3-{[(Benzyloxy)carbonyl][3-(trifluoromethyl)benzyl]amino}-8-[2-(benzyloxy)-2-oxoethyl]-8-methyl-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylic acid 在 palladium on activated charcoal N-羟基-7-氮杂苯并三氮唑 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 为溶剂， 生成 ((6S,8S)-6-[({(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl}amino)carbonyl]-8-methyl-4-oxo-3-{[3-(trifluoromethyl)benzyl]amino}-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidin-8-yl)acetic acid
  参考文献：
  名称：

  Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors

  摘要：

  A series of bicyclic pyrimidinone-based HCV NS3 protease inhibitors was synthesized via selective C8 position functionalization. Substituted phenylamides and phenylureas were preferred in the S2 binding pocket. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00022-2

文献信息

• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20030064962A1

  公开（公告）日：2003-04-03

  The present invention relates generally to a novel class of pyrimidinones of Formula (I): 1 that are useful as serine protease inhibitors, and more particularly as Hepatitis C virus NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及一种新型的嘧啶酮类化合物，具有如下式（I）所示的结构，这些化合物可用作丝氨酸蛋白酶抑制剂，更具体地作为丙型肝炎病毒NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用这些药物的方法。
• Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors
  作者：Peter W Glunz、Brent D Douty、Carl P Decicco

  DOI：10.1016/s0960-894x(03)00022-2

  日期：2003.3

  A series of bicyclic pyrimidinone-based HCV NS3 protease inhibitors was synthesized via selective C8 position functionalization. Substituted phenylamides and phenylureas were preferred in the S2 binding pocket. (C) 2003 Elsevier Science Ltd. All rights reserved.